Aveanna Healthcare Holdings AVAH
NASDAQ AVAH
$13.20 -0.05 (-0.38%)
At close: Nov 9, 2026 · 4:00 PM EST

Aveanna Healthcare Holdings (AVAH) Long-Term Investments (2021 - 2026)

Updated

Aveanna Healthcare Holdings' Long-Term Investments came in at $195.19 million for FY2026.

Analysis

Aveanna Healthcare Holdings (AVAH) Long-Term Investments (2021 - 2026) Analysis & Trends

Going back to FY2021, Aveanna Healthcare Holdings' Long-Term Investments data covers 5 years.

  • Long-Term Investments carries a five-year compound annual growth rate of -21.1% (FY2021 to FY2026).
  • The FY2026 figure represents the highest annual Long-Term Investments since FY2021.
  • Per Business Quant, earlier years put Long-Term Investments at -$122.09 million in FY2024, -$127.44 million in FY2023 and -$4.18 million in FY2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Investments (Qtr)
1 HCA Healthcare 108.44 Bn 104.53 Bn - 815.00 Mn
2 Natera 46.38 Bn 42.00 Bn 513.47 Mn -
3 Labcorp Holdings 30.37 Bn 28.45 Bn 1.11 Bn 226.30 Mn
4 Quest Diagnostics 28.52 Bn 26.28 Bn 1.04 Bn 139.00 Mn
5 Tenet Healthcare 23.21 Bn 12.51 Bn - 3.96 Bn
6 Guardant Health 21.35 Bn 16.97 Bn 236.15 Mn -
7 Tempus AI 15.33 Bn 12.48 Bn 266.70 Mn 212.28 Mn
8 BrightSpring Health Services 14.30 Bn 12.05 Bn 518.55 Mn 7.54 Mn
9 Encompass Health 13.86 Bn 13.49 Bn - -
10 Aveanna Healthcare Holdings 2.88 Bn 2.25 Bn 218.53 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jan 3, 2026 195.19 Mn
Dec 28, 2024 -122.09 Mn
Dec 30, 2023 -127.44 Mn
Dec 31, 2022 -4.18 Mn
Jan 1, 2022 637.95 Mn
Jan 2, 2021 267.17 Mn
API Access

Aveanna Healthcare Holdings Long-Term Investments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=long-term-investments&ticker=AVAH&period=max&api_key=YOUR_API_KEY